A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2017

At a glance

  • Drugs Salmeterol (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Neothetics
  • Most Recent Events

    • 26 Jun 2017 Top-Line results from this trial published in a Neothetics Media Release.
    • 20 Mar 2017 According to a Neothetics media release, last subject has been enrolled in this trial. The trial has enrolled approximately 150 subjects. Top-line data expected in June 2017.
    • 20 Mar 2017 Status changed from recruiting to active, no longer recruiting, as reported in a Neothetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top